GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations below 10 nM, GZD824 significantly suppresses FLT3, F...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuting, Zhang, Lenghe, Tang, Xia, Luo, Jinfeng, Tu, Zhengchao, Jiang, Kaili, Ren, Xiaomei, Xu, Fang, Chan, Shingpan, Li, Yuhua, Zhang, Zhang, Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125355/
https://www.ncbi.nlm.nih.gov/pubmed/32247263
http://dx.doi.org/10.1016/j.tranon.2020.100766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125355/
https://www.ncbi.nlm.nih.gov/pubmed/32247263
http://dx.doi.org/10.1016/j.tranon.2020.100766

Ejemplares similares